AMGN · Full Picture

AMGEN INC — the full picture

Earnings window · 2026-08-05 to 2026-11-09 · anchored on the 10-Q report

One earnings window, everything merged: the filing, the call, press releases and news digests, folded into ranked threads.

What to look at first

  1. Revenue Performance and Mix · Revenue growth & mixPriority 89
    +0.1% cash; 4 sources (news, press_release, sec_filing, transcript); 3 forward row(s); structured_verified
    Amgen's Repatha sales increased 37% year over year to $1.09 billion, exceeding the Zacks Consensus Estimate of $1.04 billion.
  2. Guidance and Outlook · Guidance & outlookPriority 88
    +0.6% revenue; 4 sources (news, press_release, sec_filing, transcript); 9 forward row(s); quote_verified
    Amgen raised full-year 2026 guidance to total revenue between US$38.20 billion and US$39.40 billion.
  3. Operating Expense Trends · Operating expenses (SG&A)Priority 84
    -125.1% operating_income; 4 sources (news, press_release, sec_filing, transcript); 2 forward row(s); structured_verified
    Total estimated future amortization of finite-lived intangible assets remaining: six months ending Dec 31, 2026 $1.8 billion; 2027 $3.6 billion; 2028 $2.8 billion; 2029 $2.3 billion; 2030 $2.2 billion; 2031 $2.1 billion
  4. Operating Cash Flow Trends · Cash flow generationPriority 81
    +17.6% cash (realized); 3 sources (news, press_release, sec_filing); structured_verified
    Net cash provided by operating activities was $6,191 million for the six months ended June 30, 2026 and $3,671 million for the six months ended June 30, 2025.
  5. Operating Income and Margins · Operating income & profitabilityPriority 79
    +31.9% operating_income (realized); 3 sources (news, press_release, sec_filing); quote_verified
    Operating income for the six months ended June 30, 2026: $6,180 million; for the six months ended June 30, 2025: $3,834 million.
  6. Liquidity and Debt Position · Debt, leverage & refinancingPriority 73
    -9.5% liability (realized); 2 sources (news, sec_filing); 1 forward row(s); structured_verified
    During the six months ended June 30, 2026, we repaid the €750 million aggregate principal amount of our 2.00% 2026 euro Notes ($833 million upon settlement of the related cross-currency swap), compared to $3.5 billion of debt repayments during the six months ended June 30, 2025.
  7. Capital Expenditures Program · Capital expenditurePriority 71
    -2.3% cash; 4 sources (news, press_release, sec_filing, transcript); 2 forward row(s); structured_verified
    Cash used in investing activities during the six months ended June 30, 2026 and 2025 was primarily due to capital expenditures of $1.2 billion and $780 million, respectively, including construction costs for new plants and expansion of manufacturing capacity.
  8. Competition and Pricing Pressure · Competition & market sharePriority 71
    3 sources (news, press_release, sec_filing); quote_verified
    For the remainder of 2026, we continue to expect accelerated sales erosion driven by increased competition, as multiple biosimilars have launched in the United States and ROW.
  9. Quarterly Dividend Declaration · Buybacks & dividendsPriority 66
    3 sources (news, press_release, sec_filing); 2 forward row(s); quote_verified
    Amgen declared a quarterly dividend of $2.52 per share.
  10. Market Demand Trends · Demand, orders & backlogPriority 61
    +3.7% revenue (realized); 3 sources (news, sec_filing, transcript); 1 forward row(s); quote_verified
    TEZSPIRE sales grew 43% year-over-year to $538 million in Q3 2026.
  11. IRS Tax Disputes · UnclassifiedPriority 58
    -1.8% liability; 8 forward row(s); structured_verified
    The IRS Notices for years 2010–2012 seek to increase our U.S. taxable income for those years by an amount that would result in additional federal tax of approximately $3.6 billion, plus interest, reduced by up to approximately $900 million of repatriation tax previously accrued and paid.
  12. Medicare Drug Price Setting · UnclassifiedPriority 57
    3 forward row(s); quote_verified
    CMS selected Otezla for Medicare price setting in January 2025, applicable beginning in 2027, and Amgen expects further net selling price declines beginning in 2027.

Threads by pillar

Revenue & Demand Priority 95 · 9 threads

Costs & Margins Priority 91 · 6 threads

Capital & Balance Sheet Priority 94 · 8 threads

Strategy & Portfolio Priority 60 · 5 threads

Legal, Regulatory & Policy Priority 76 · 7 threads

Guidance & Outlook Priority 88 · 1 thread

Macro & Market Conditions Priority 84 · 5 threads

Management & Governance Priority 34 · 3 threads

Unclassified Priority 84 · 5 threads

Expected impact by metric

metricforward netforward grossrealized
operating_income-125.1%+125.1%+42.9%
cash-4.3%+4.6%+25.7%
liability-1.8%+2.4%-9.5%
assets+2.3%+2.3%+6.5%
revenue+1.1%+1.1%+55.4%
margin——+9.6%
net_income——+10.3%